Xilio Therapeutics Inc (XLO) PT Lowered to $25 at Guggenheim
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts XLO Hot Sheet
Price: $8.68 --0%
Rating Summary:
7 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Rating Summary:
7 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Join SI Premium – FREE
Guggenheim analyst Michael W. Schmidt lowered the price target on Xilio Therapeutics Inc (NASDAQ: XLO) to $25.00 (from $40.00) while maintaining a Buy rating.
You May Also Be Interested In
- Xilio Therapeutics to Present at the Stifel 2026 Healthcare Conference
- Ideaya Biosciences (IDYA) PT Lowered to $45 at RBC Capital
- Graphic Packaging Holding Company (GPK) PT Raised to $12 at RBC Capital
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
